Aurélien Marabelle
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Immunology top 0.2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 227
- Cancer Immunotherapy and Biomarkers 189
- CAR-T cell therapy research 65
- Colorectal Cancer Treatments and Studies 24
- Immunology 100
- Immunotherapy and Immune Responses 60
- Immune Cell Function and Interaction 31
- Co-authors
- Stéphane Champiat (76 shared papers)Jean‐Charles Soria (44 shared papers)Laurence Zitvogel (18 shared papers)Christophe Massard (48 shared papers)Guido Kroemer (12 shared papers)Roch Houot (11 shared papers)Samy Ammari (29 shared papers)Holbrook E. Kohrt (17 shared papers)
- Journals
- Annals of Oncology (51 papers)European Journal of Cancer (37 papers)Journal of Clinical Oncology (31 papers)Journal for ImmunoTherapy of Cancer (15 papers)Cancer Research (12 papers)
- Partner nations
- FranceUnited StatesSpain
In The Last Decade
Aurélien Marabelle
269 papers receiving 15.0k citations
Aurélien Marabelle's Hit Papers
Peers
Comparison fields: 5 of 136
- Oncology 10.2k
- Immunology 5.8k
- Cancer Research 1.6k
- Pulmonary and Respiratory Medicine 3.1k
- Radiology, Nuclear Medicine and Imaging 1.7k
Countries citing papers authored by Aurélien Marabelle
This map shows the geographic impact of Aurélien Marabelle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurélien Marabelle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurélien Marabelle more than expected).
Fields of papers citing papers by Aurélien Marabelle
This network shows the impact of papers produced by Aurélien Marabelle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurélien Marabelle. The network helps show where Aurélien Marabelle may publish in the future.
Co-authors
The 25 scholars most cited alongside Aurélien Marabelle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 281 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy Hit paper breakdown → | 2016 | 976 |
| 2 | Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 Hit paper breakdown → | 2016 | 867 |
| 3 | A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study Hit paper breakdown → | 2018 | 825 |
| 4 | Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination Hit paper breakdown → | 2016 | 813 |
| 5 | Cancer vaccines: the next immunotherapy frontier Hit paper breakdown → | 2022 | 553 |
| 6 | Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors Hit paper breakdown → | 2018 | 376 |
| 7 | Intratumoural administration and tumour tissue targeting of cancer immunotherapies Hit paper breakdown → | 2021 | 342 |
| 8 | 2013 | 279 | |
| 9 | Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study Hit paper breakdown → | 2022 | 273 |
| 10 | Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer Hit paper breakdown → | 2019 | 272 |
| 11 | 2018 | 268 | |
| 12 | 2017 | 266 | |
| 13 | 2013 | 251 | |
| 14 | 2015 | 248 | |
| 15 | 2017 | 244 | |
| 16 | Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study Hit paper breakdown → | 2022 | 240 |
| 17 | 2013 | 229 | |
| 18 | Tumour burden and efficacy of immune-checkpoint inhibitors Hit paper breakdown → | 2021 | 209 |
| 19 | 2018 | 201 | |
| 20 | Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies Hit paper breakdown → | 2021 | 196 |
About Aurélien Marabelle
Aurélien Marabelle is a scholar working on Oncology, Immunology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Cancer Research, having authored 281 papers that have together received 15.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (189 papers), CAR-T cell therapy research (65 papers), Immunotherapy and Immune Responses (60 papers), Immune Cell Function and Interaction (31 papers), Cancer Genomics and Diagnostics (26 papers), Colorectal Cancer Treatments and Studies (24 papers), Genetic factors in colorectal cancer (21 papers) and Lung Cancer Treatments and Mutations (20 papers). The work is most often cited by research in Oncology (10.2k citations), Immunology (5.8k citations), Cancer Research (1.6k citations), Pulmonary and Respiratory Medicine (3.1k citations) and Radiology, Nuclear Medicine and Imaging (1.7k citations). Aurélien Marabelle has collaborated with scholars based in France, United States and Spain. Frequent co-authors include Stéphane Champiat, Jean‐Charles Soria, Laurence Zitvogel, Christophe Massard, Guido Kroemer, Roch Houot, Samy Ammari, Holbrook E. Kohrt, Alexander Eggermont and Sophie Postel‐Vinay. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.